[go: up one dir, main page]

AR103726A1 - Cristales de anticuerpos monoclonales anti-pd-1 humanos - Google Patents

Cristales de anticuerpos monoclonales anti-pd-1 humanos

Info

Publication number
AR103726A1
AR103726A1 ARP160100432A ARP160100432A AR103726A1 AR 103726 A1 AR103726 A1 AR 103726A1 AR P160100432 A ARP160100432 A AR P160100432A AR P160100432 A ARP160100432 A AR P160100432A AR 103726 A1 AR103726 A1 AR 103726A1
Authority
AR
Argentina
Prior art keywords
crystals
monoclonal antibody
human anti
antibody crystals
cancers
Prior art date
Application number
ARP160100432A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR103726A1 publication Critical patent/AR103726A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan cristales de pembrolizumab y anticuerpos monoclonales anti-PD-1 (receptor de superficie celular humana de muerte celular programada 1) estructuralmente similares, así como procedimientos de producción de dichos cristales y usos de composiciones que comprenden dichos cristales de anticuerpo, por ejemplo en el tratamiento de cánceres.
ARP160100432A 2015-02-27 2016-02-18 Cristales de anticuerpos monoclonales anti-pd-1 humanos AR103726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562121867P 2015-02-27 2015-02-27

Publications (1)

Publication Number Publication Date
AR103726A1 true AR103726A1 (es) 2017-05-31

Family

ID=56789127

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100432A AR103726A1 (es) 2015-02-27 2016-02-18 Cristales de anticuerpos monoclonales anti-pd-1 humanos

Country Status (13)

Country Link
US (1) US11014986B2 (es)
EP (1) EP3261663B1 (es)
JP (1) JP6999419B2 (es)
KR (1) KR102622285B1 (es)
CN (1) CN107249624B (es)
AR (1) AR103726A1 (es)
AU (2) AU2016223047A1 (es)
BR (1) BR112017016434A8 (es)
CA (1) CA2975623A1 (es)
MX (1) MX391190B (es)
RU (1) RU2017133449A (es)
TW (1) TWI714552B (es)
WO (1) WO2016137850A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
KR20200119844A (ko) * 2018-02-13 2020-10-20 머크 샤프 앤드 돔 코포레이션 항-pd-1 항체를 사용한 암의 치료 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US11890285B2 (en) 2019-09-24 2024-02-06 Mirati Therapeutics, Inc. Combination therapies
KR20230053614A (ko) * 2020-07-31 2023-04-21 메사추세츠 인스티튜트 오브 테크놀로지 고체 형태의 폴리펩티드를 포함하는 조성물 및 관련 방법
EP4228692A1 (en) * 2020-10-13 2023-08-23 ImmunoVaccine Technologies Inc. Methods of treating diffuse large b-cell lymphoma
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6402051B1 (en) 2000-10-27 2002-06-11 Deere & Company Fold cylinder structure
EP1801123A3 (en) 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
KR20030074693A (ko) 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US6955717B2 (en) 2001-05-01 2005-10-18 Medimmune Inc. Crystals and structure of Synagis Fab
EP1492554B1 (en) 2001-06-21 2019-08-21 Althea Technologies, Inc. Spherical protein particles
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2006133486A1 (en) * 2005-06-14 2006-12-21 The Macfarlane Burnet Institute For Medical Research And Public Health Limited CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTOR:Fc COMPLEXES AND USES THEREOF
KR20090101893A (ko) 2006-10-27 2009-09-29 애보트 바이오테크놀로지 리미티드 결정형 항-ｈＴＮＦ알파 항체
CN101605906A (zh) * 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
EP2527364A1 (en) 2007-03-29 2012-11-28 Abbott Laboratories Crystalline anti-human IL-12 antibodies
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PL2242773T3 (pl) * 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
CA2772613C (en) * 2009-09-03 2020-03-10 Schering Corporation Anti-gitr antibodies
BR112012005869A2 (pt) * 2009-09-15 2017-01-31 Althea Tech Inc cristais da proteína a, cristais reticulados e métodos de utilização dos mesmos
WO2012135035A1 (en) 2011-03-25 2012-10-04 Amgen Inc. Anti - sclerostin antibody crystals and formulations thereof
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
CA2918419C (en) * 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
NZ735820A (en) 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody

Also Published As

Publication number Publication date
MX391190B (es) 2025-03-21
BR112017016434A8 (pt) 2023-04-11
BR112017016434A2 (pt) 2018-04-10
CA2975623A1 (en) 2016-09-01
RU2017133449A (ru) 2019-03-27
EP3261663A4 (en) 2018-10-03
CN107249624B (zh) 2023-01-31
EP3261663A1 (en) 2018-01-03
US20180237524A1 (en) 2018-08-23
JP6999419B2 (ja) 2022-02-10
EP3261663B1 (en) 2025-09-24
WO2016137850A1 (en) 2016-09-01
TWI714552B (zh) 2021-01-01
KR20170120155A (ko) 2017-10-30
AU2016223047A1 (en) 2017-07-13
CN107249624A (zh) 2017-10-13
KR102622285B1 (ko) 2024-01-05
AU2022200142A1 (en) 2022-02-10
US11014986B2 (en) 2021-05-25
JP2018510142A (ja) 2018-04-12
AU2022200142B2 (en) 2024-08-01
RU2017133449A3 (es) 2019-08-28
MX2017011003A (es) 2017-10-20
TW201639886A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
AR103726A1 (es) Cristales de anticuerpos monoclonales anti-pd-1 humanos
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2018000992A2 (es) Anticuerpos anti-pd-1 novedosos
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2017002244A1 (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización. (divisional de solicitud 2829-2015).
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2018001530A (es) Anticuerpos anti-pd-l1 novedosos.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
CA2971734C (en) Anti-pd-1 antibodies
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
MX2016003103A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores.
EA201891983A8 (ru) Комбинированная терапия антителами к cd73